BlackThorn Therapeutics, a South San Francisco, CA-based Calif.-based clinical stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, closed a $14m extension of its Series A financing.
Backers included GV (formerly Google Ventures) and Biomatics Capital, which joined ARCH Venture Partners, Johnson & Johnson Innovation – JJDC, Inc., Mercury Fund, Alexandria Real Estate Equities and Altitude Life Science Ventures and brought total Series A financing to $54m.
The company intends to use the funds to progress its lead clinical-stage asset, BTRX-246040, through Phase 2 clinical development, as well as to conduct additional exploratory pilot studies in targeted indications.
Led by Mark Corrigan, M.D., executive chairman, BlackThorn leverages its INFORM™ platform, which supports the discovery and development of targeted treatments by linking brain physiology to behavior using advanced functional imaging and objective assessment tools that quantify emotion and behavior.
BTRX-246040, its lead program, is an antagonist of the nociceptin receptor (NOPR) and a target linked to multiple neurobehavioral disorders.